Evidence map›Paper›PMID 23775025›Full record

ArticleCancer causes & control : CCC2013

Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.

Jennifer D Brooks, Sharon N Teraoka, Leslie Bernstein, Lene Mellemkjær, Kathleen E Malone, Charles F Lynch, Robert W Haile, Patrick Concannon, Anne S Reiner, David J Duggan and 4 more

Open access · hybridAbstract readComparative Study
In one paragraph

Article in Cancer causes & control : CCC, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Role of Germline Genetics in Identifying Survivors at Risk for Adverse Effects of Cancer Treatment.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Jennifer D BrooksDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 307 E 63rd Street, 3rd Floor, New York, NY, USA. brooksj@mskcc.org
Sharon N Teraoka
Leslie Bernstein
Lene Mellemkjær
Kathleen E Malone
Charles F Lynch
Robert W Haile
Patrick Concannon
Anne S Reiner
David J Duggan
Katherine Schiermeyer
WECARE Study Collaborative Group
Jonine L Bernstein
Jane C Figueiredo
Memorial Sloan Kettering Cancer Center · USCity of Hope · USStanford Cancer InstituteTranslational Genomics Research Institute · USUniversity of Iowa · USFred Hutch Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Brandi Janssen · 1990 to 2026
$40.5M
Genome-Wide Association Study of Radiation Exposure and Bilateral Breast CancerR01CA129639 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BERNSTEIN, JONINE L. · 2009 to 2013
$15.6M
BREAST CANCER, RADIATION EXPOSURE, AND THE ATM GENEU01CA083178 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BERNSTEIN, JONINE LISA · 1999 to 2003
$9.3M
Interaction of Radiation, BRCA1/2, and Breast CancerR01CA097397 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BERNSTEIN, JONINE LISA · 2002 to 2006
$4.1M
Research and Mentoring on Energetic Factors and Cancer: Established InvestigatorK05CA136967 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BERNSTEIN, LESLIE · 2009 to 2013
$684k
Pharmacogenetics of Tamoxifen and Chemotherapies and Risk of Contralateral BreastR03CA139583 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FIGUEIREDO, JANE C. · 2009 to 2010
$163k
NCI NIH HHS K05 CA136967NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA097397NCI NIH HHS R01CA097397NCI NIH HHS R01 CA129639NCI NIH HHS R03 CA139583NCI NIH HHS R03CA139583NCI NIH HHS U01 CA083178NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

purposeWomen who receive chemotherapy for a first primary breast cancer have been observed to have a reduced risk of contralateral breast cancer (CBC), however, whether the genetic profile of a patient modifies this protective effect is currently not understood. The purpose of this study is to investigate the impact of germline genetic variation in genes coding for drug metabolizing enzymes, transporters, and targets on the association between chemotherapy and risk of CBC.

methodsFrom the population-based Women's Environment Cancer and Radiation Epidemiology (WECARE) Study, we included 636 Caucasian women with CBC (cases) and 1,224 women with unilateral breast cancer (controls). The association between common chemotherapeutic regimens, CMF and FAC/FEC, and risk of CBC stratified by genotype of 180 single nucleotide polymorphisms in 14 genes selected for their known involvement in metabolism, action, and transport of breast cancer chemotherapeutic agents, were determined using conditional logistic regression.

resultsCMF (RR = 0.5, 95 % CI 0.4, 0.7) and FAC/FEC (RR = 0.7, 95 % CI 0.4, 1.0) are associated with lower CBC risk relative to no chemotherapy in multivariable-adjusted models. Here we show that genotype of selected genes involved in the metabolism and uptake of these therapeutic agents does not significantly alter the protective effect of either CMF or FAC/FEC on risk of CBC.

conclusionThe results of this study show that germline genetic variation in selected gene does not significantly alter the protective effect of CMF, FAC, and FEC on risk of CBC.

Indexed as

Genetic Predisposition to DiseasePharmacogeneticsAdultAgedAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsCase-Control StudiesCytochrome P-450 Enzyme SystemDNA, NeoplasmFemaleFollow-Up StudiesGenome-Wide Association StudyGenotypeGerm-Line MutationHumansAntineoplastic AgentsBiomarkers, TumorCytochrome P-450 Enzyme SystemDNA, NeoplasmMembrane Transport ProteinsMethyltransferases

Identifiers

PMID23775025
PMCPMC3709075
OpenAlexW2022220168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.